[go: up one dir, main page]

DK0713393T3 - Östrogenforbindelser som anti-angiogenesemidler - Google Patents

Östrogenforbindelser som anti-angiogenesemidler

Info

Publication number
DK0713393T3
DK0713393T3 DK94924120T DK94924120T DK0713393T3 DK 0713393 T3 DK0713393 T3 DK 0713393T3 DK 94924120 T DK94924120 T DK 94924120T DK 94924120 T DK94924120 T DK 94924120T DK 0713393 T3 DK0713393 T3 DK 0713393T3
Authority
DK
Denmark
Prior art keywords
angiogenic agents
estrogen compounds
arthritis
estrogen
compounds
Prior art date
Application number
DK94924120T
Other languages
Danish (da)
English (en)
Inventor
Amato Robert John D
Moses Judah Folkman
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of DK0713393T3 publication Critical patent/DK0713393T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94924120T 1993-08-06 1994-08-02 Östrogenforbindelser som anti-angiogenesemidler DK0713393T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/102,767 US5504074A (en) 1993-08-06 1993-08-06 Estrogenic compounds as anti-angiogenic agents

Publications (1)

Publication Number Publication Date
DK0713393T3 true DK0713393T3 (da) 2006-05-08

Family

ID=22291581

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05016659T DK1640009T3 (da) 1993-08-06 1994-08-02 Östrogenforbindelser som antimitotiske midler
DK94924120T DK0713393T3 (da) 1993-08-06 1994-08-02 Östrogenforbindelser som anti-angiogenesemidler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05016659T DK1640009T3 (da) 1993-08-06 1994-08-02 Östrogenforbindelser som antimitotiske midler

Country Status (11)

Country Link
US (8) US5504074A (fr)
EP (3) EP0713393B1 (fr)
JP (3) JPH09501433A (fr)
AT (2) ATE411029T1 (fr)
AU (1) AU7450994A (fr)
CA (1) CA2168850C (fr)
DE (2) DE69434584T2 (fr)
DK (2) DK1640009T3 (fr)
ES (2) ES2255704T3 (fr)
PT (1) PT1640009E (fr)
WO (1) WO1995004535A1 (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) * 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
AU5984196A (en) * 1995-06-07 1996-12-30 Merck & Co., Inc. Treatment and prevention of prostatic disease
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030195180A1 (en) * 1995-12-12 2003-10-16 D'amato Robert John Estrogenic compounds as anti-mitotic agents
JP4228116B2 (ja) * 1996-05-09 2009-02-25 ゼニス・オペレイションズ・プロプライエタリー・リミテッド 喘息および気道の疾患の治療
PT930876E (pt) * 1996-07-22 2005-01-31 Renovo Ltd Utilizacao de moduladores da funcao esteroide sexual para tratar feridas e desordens fibroticas
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
DE19654750A1 (de) * 1996-12-30 1998-07-02 Helmut Dr Med Zander Verwendung von Wirkstoffen mit Östrogen-Wirkung zur Vorbeugung und Behandlung von Makuladegeneration
AU6696698A (en) * 1997-03-11 1998-09-29 Allergan Sales, Inc. Anti-angiogenic agents
WO1998042328A1 (fr) 1997-03-26 1998-10-01 Biosource Technologies, Inc. Ethers di-aryle et leurs derives utilises comme agents anticancereux
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
US6355630B1 (en) 1997-10-23 2002-03-12 American Home Products Corporation Estra-1,3,5(10)-triene-7α-thioethers
US6689768B2 (en) * 1998-04-15 2004-02-10 Jenapharm Gmbh & Co. Kg Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
DK1520588T3 (en) 1998-07-13 2015-03-23 Univ Texas Use of antibodies to aminophospholipids for cancer treatment
WO2000007576A2 (fr) * 1998-08-07 2000-02-17 Endorecherche, Inc. INHIBITION DE LA 3$G(a)-HYDROXYSTEROID-DESHYDROGENASE DE TYPE 3
AU764266B2 (en) 1998-08-11 2003-08-14 Entremed, Inc Use of estrogenic and anti-estrogenic compounds as anti-fungal compounds
EP1234585A3 (fr) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Compositions pour la prévention ou le traitement du cancer
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
WO2001014405A2 (fr) * 1999-08-23 2001-03-01 Entremed, Inc. Procedes d'obtention de 2-methoxyestradiol tres pur
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US6696436B1 (en) 1999-10-26 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services B-homoestra-1,3,5(10)-trienes as modulators of tubulin polymerization
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
AU8838601A (en) * 2000-11-27 2002-06-03 Entremed Inc Antiangiogenic agents
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
WO2003006002A1 (fr) * 2001-07-13 2003-01-23 Oxigene, Inc. Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US7488723B2 (en) * 2001-09-05 2009-02-10 Alcon, Inc. Use of non-feminizing estrogens as treatment for retinal vascular diseases
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US7023931B2 (en) * 2001-11-05 2006-04-04 Texas Instruments Incorporated System and method for soft slicing
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
US20030236439A1 (en) * 2002-01-30 2003-12-25 Gregory Agoston Non-steroidal analogs of 2-methoxyestradiol
AU2003217754A1 (en) * 2002-03-01 2003-09-16 Entremed, Inc. New methods of using antiangiogenic agents
CA2489712C (fr) * 2002-06-21 2016-07-12 University Of Utah Research Foundation Composes reticules et leurs procedes de preparation et d'utilisation
SI2269656T1 (sl) 2002-07-15 2014-11-28 Board Of Regents, The University Of Texas System Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006525030A (ja) * 2003-05-07 2006-11-09 セダーズ−シナイ メディカル センター 細胞内エストラジオール結合タンパク質、このタンパク質をコードするポリヌクレオチドおよびこのタンパク質を過剰発現する細胞
EP1624935B1 (fr) 2003-05-15 2016-09-28 The University of Utah Research Foundation Composites anti-adherence et methodes d'utilisation desdits composites
AU2004275693A1 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US20050032766A1 (en) * 2003-08-05 2005-02-10 Green Shawn J. Use of estrogenic compounds as anti-fungal agents
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005051357A1 (fr) * 2003-11-19 2005-06-09 Entremed, Inc. Agents antiangiogenes
ZA200604869B (en) 2003-12-04 2007-11-28 Univ Utah Res Found Modified macromolecules and methods of making and using thereof
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CN1953743B (zh) 2004-01-22 2010-12-08 迈阿密大学 局部辅酶q10制剂及其使用方法
EP1756139A4 (fr) * 2004-03-12 2009-07-29 Entremed Inc Agents anti-angiogeniques
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
WO2005105106A2 (fr) * 2004-04-21 2005-11-10 Roby Russell R Traitement hormonal de la degenerescence maculaire
US20050239758A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2005110374A1 (fr) * 2004-04-30 2005-11-24 Allergan, Inc. Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2005107708A1 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
JP2007536251A (ja) * 2004-05-04 2007-12-13 チルドレンズ メディカル センター コーポレーション 子癇前症の処置のための方法および組成物
BRPI0513243B8 (pt) * 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
TW200611909A (en) * 2004-08-04 2006-04-16 Akzo Nobel Nv Process for the preparation 2-substituted-derivatives of estrone and estradiol
TW200613316A (en) * 2004-08-26 2006-05-01 Akzo Nobel Nv Process for the preparation of estrone and/or estradiol-derivates
MX2007003522A (es) 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
US20060148674A1 (en) * 2004-12-31 2006-07-06 Luduena Richard F Therapeutic composition
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use
US8168621B2 (en) 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US7627508B2 (en) * 2006-01-04 2009-12-01 S.R. Clarke, Inc. Method for tracking employees
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US20070203227A1 (en) * 2006-02-24 2007-08-30 Herman Adlercreutz Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors
WO2007109312A2 (fr) * 2006-03-20 2007-09-27 Entremed, Inc. 2-méthoxyestradiol présentant une activité anti-arthritique pouvant modifier l'évolution de la maladie
AU2007240613B2 (en) * 2006-04-20 2013-11-28 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080032920A1 (en) * 2006-07-11 2008-02-07 Prestwich Glenn D Macromolecules modified with electrophilic groups and methods of making and using thereof
JP5290189B2 (ja) * 2006-11-30 2013-09-18 エンディース エルエルシー ６−アルコキシアルキルエストラジオール誘導体およびその使用
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008094665A1 (fr) * 2007-01-31 2008-08-07 Entremed, Inc. Procédé de traitement des maladies associées à l'amylose
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
WO2008137599A2 (fr) * 2007-05-01 2008-11-13 Evestra, Inc. Analogues de 2-alcoxyestradiol et préparations pharmaceutiques
JP5809415B2 (ja) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド 抗ｖｅｇｆ抗体の組成物および方法
EP2633864A1 (fr) 2008-07-25 2013-09-04 The Regents of the University of Colorado Inhibiteurs de clip et procédés de modulation de la fonction immune
US7901904B2 (en) * 2008-10-16 2011-03-08 Naxospharma S.R.L. Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds
WO2010132498A1 (fr) * 2009-05-11 2010-11-18 Oxigene, Inc. Agents d'interruption vasculaire utilises dans le traitement de la vasculopathie choroïdienne polypoïdale
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
ES2605960T3 (es) * 2010-09-14 2017-03-17 Endece, Llc Derivados de desmetil-estradiol 6-sustituido como agonistas del RE-beta
US9056923B2 (en) 2010-12-10 2015-06-16 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphagiogenesis-dependent diseases
US20120225849A1 (en) * 2011-03-01 2012-09-06 The University Of Kansas 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition
WO2013010045A1 (fr) 2011-07-12 2013-01-17 Biotime Inc. Nouveaux procédés et formulations pour thérapie cellulaire orthopédique
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3040075B1 (fr) * 2014-12-30 2017-09-13 Curadis GmbH Stéroïdes C-19 pour l'inhibition de la néovascularisation
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018145109A1 (fr) 2017-02-06 2018-08-09 Massachusetts Institute Of Technology Méthodes et produits associés à des inhibiteurs de glutaminase
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
WO2020247054A1 (fr) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines et leurs utilisations
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2584271A (en) * 1948-06-19 1952-02-05 Searle & Co Steroid derivatives and method for producing the same
GB857081A (en) 1956-05-29 1960-12-29 Syntex Sa Cyclopentanophenanthrene derivatives and process for the production thereof
US3166577A (en) * 1956-05-29 1965-01-19 Syntex Corp 1, 2-dimethyl estrogens and intermediates used in the production thereof
GB857080A (en) 1956-05-29 1960-12-29 Syntex Sa Cyclopentanophenanthrene derivatives and process for the production thereof
US2846453A (en) * 1957-05-28 1958-08-05 Searle & Co Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers
JPS42928Y1 (fr) 1964-07-25 1967-01-19
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US3470218A (en) * 1966-12-27 1969-09-30 Allied Chem New 2-substituted estrogenic steroids
US3410879A (en) * 1967-04-12 1968-11-12 American Home Prod Process for preparing gonahexaenes
US3492321A (en) * 1968-01-22 1970-01-27 Syntex Corp Cyclopropenyl estra, -1,3,5(10)-trienes
US3496272A (en) * 1968-01-23 1970-02-17 American Home Prod Ester of 3-(2-propynyloxy)-estradiol
US3487155A (en) 1968-02-19 1969-12-30 Sandoz Ag Substituted estradiol alkyl ethers
DE2004516A1 (en) 1969-03-05 1970-09-10 VEB Jenapharm, Jena Thermpentic steroidal sulphonate esters
US3950437A (en) 1972-12-25 1976-04-13 Oxirane Chemical Co. Method for manufacture of dihydric phenols
GB1502635A (en) * 1974-02-27 1978-03-01 Schering Ag Process for splitting steroid ethers
JPS5265259A (en) 1975-11-27 1977-05-30 Takeda Chem Ind Ltd Synthesis of 16beta-alkylestradiol or its 17-esters
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
US4172132A (en) * 1977-07-26 1979-10-23 Schering Corporation 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
DE2757157C3 (de) 1977-12-19 1980-10-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 16 a -alkylierten Steroiden
FR2515188A1 (fr) * 1981-10-27 1983-04-29 Roussel Uclaf Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
FI830078A7 (fi) 1982-01-15 1983-07-16 Lilly Co Eli Askorbiinihappoeettereitä ja niitä lähellä olevia yhdisteitä.
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4522758A (en) * 1983-12-22 1985-06-11 Eli Lilly And Company Method of preparing 2-fluoro-17β-estradiol
DE3583900D1 (de) 1984-06-06 1991-10-02 Abbott Lab Adrenergische verbindungen.
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
SU1240038A1 (ru) 1984-11-23 1996-10-27 Уральский политехнический институт им.С.М.Кирова 3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью
EP0243449A1 (fr) 1985-10-18 1987-11-04 The Upjohn Company Hydrocarbures cycliques avec chaine laterale aminoalkyle
JPS62135472A (ja) 1985-12-10 1987-06-18 Yakult Honsha Co Ltd 新規な１，２−ビス−３，５−ジオキソピペラジニルエタン誘導体
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
JP2544136B2 (ja) 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2517561B2 (ja) 1986-10-03 1996-07-24 新技術事業団 カテコ−ルエストロゲンのイムノアツセイキツド
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
KR960002913B1 (ko) 1987-04-16 1996-02-28 디 업존 캄파니 아미노알킬 측쇄를 갖는 사이클릭 탄화수소
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
JPH01240038A (ja) 1988-03-19 1989-09-25 Fujitsu Ltd ピーク値比較型タイミング再生方式
JPH04506066A (ja) 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
JPH03240726A (ja) 1990-02-15 1991-10-28 Fujisawa Pharmaceut Co Ltd 化学療法効果増強剤
JPH0446120A (ja) 1990-06-11 1992-02-17 Kyowa Hakko Kogyo Co Ltd 血管新生抑制剤
IT1247827B (it) 1991-02-05 1995-01-02 Erba Carlo Spa Benzoil carbinolo e suoi esteri, utili come inibitori dell'angiogenesi
WO1993003729A1 (fr) * 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. Phenoxazines n-substituees utilisees dans le traitement de cellules cancereuses resistant a de multiples medicaments
US6011024A (en) * 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
EP0614463B1 (fr) * 1991-11-22 2003-02-12 Alcon Laboratories, Inc. Stero des angiostatiques
PL171920B1 (pl) 1991-12-02 1997-06-30 Cor Therapeutics Inc Sposób wytwarzania nowego, hamujacego PDGF-R polipeptydy immunoglobulinowego PL
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4235657A1 (de) * 1992-10-22 1994-06-23 Schering Ag Verfahren zum Alkylieren von Östronderivaten
WO1994015594A1 (fr) * 1993-01-11 1994-07-21 Tsumura & Co. Inhibiteur de vascularisation et nouveau compose
AU6989094A (en) * 1993-05-27 1994-12-20 Entremed, Inc Compositions and methods for treating cancer and hyperproliferative disorders
US5643900A (en) * 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6908910B2 (en) * 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
WO1995029242A1 (fr) * 1994-04-26 1995-11-02 The Children's Medical Center Corporation Angiostatine et procede d'utilisation de ladite substance pour inhiber l'angiogenese
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
WO1997034876A1 (fr) * 1996-03-15 1997-09-25 Zeneca Limited Derives de cinnoline et leur emploi comme medicaments
JP4228116B2 (ja) * 1996-05-09 2009-02-25 ゼニス・オペレイションズ・プロプライエタリー・リミテッド 喘息および気道の疾患の治療
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5763432A (en) * 1997-01-29 1998-06-09 Sri International Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
US6136992A (en) * 1997-03-13 2000-10-24 The United States Of America As Represented By The Department Of Health And Human Services 2-alkoxy estradiols and derivatives thereof
US6051726A (en) 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols
CA2208916A1 (fr) 1997-07-03 1999-01-03 Hyal Pharmaceutical Corporation Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
WO1999022728A1 (fr) 1997-10-31 1999-05-14 Arch Development Corporation Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6046186A (en) 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
JPH11209322A (ja) 1998-01-27 1999-08-03 Kao Corp イソバニリルアルコール誘導体
WO2000007576A2 (fr) 1998-08-07 2000-02-17 Endorecherche, Inc. INHIBITION DE LA 3$G(a)-HYDROXYSTEROID-DESHYDROGENASE DE TYPE 3
AU764266B2 (en) * 1998-08-11 2003-08-14 Entremed, Inc Use of estrogenic and anti-estrogenic compounds as anti-fungal compounds
AU5687199A (en) 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
US6284789B1 (en) * 1998-09-04 2001-09-04 The Research Foundation Of State University Of New York Formation and composition of new optically active compounds
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
US6358940B1 (en) * 1999-09-07 2002-03-19 Rutgers, The State University Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity

Also Published As

Publication number Publication date
JPH09501433A (ja) 1997-02-10
US20030236408A1 (en) 2003-12-25
PT1640009E (pt) 2008-12-22
JP2008120840A (ja) 2008-05-29
US5892069A (en) 1999-04-06
DE69434584T2 (de) 2006-07-13
EP1927359A3 (fr) 2008-06-11
EP0713393B1 (fr) 2005-12-21
ES2255704T3 (es) 2006-07-01
DE69435151D1 (de) 2008-11-27
US20030096800A1 (en) 2003-05-22
US5504074A (en) 1996-04-02
JP2008120839A (ja) 2008-05-29
WO1995004535A1 (fr) 1995-02-16
US20030055029A1 (en) 2003-03-20
ATE313327T1 (de) 2006-01-15
EP1640009B1 (fr) 2008-10-15
AU7450994A (en) 1995-02-28
HK1014504A1 (en) 1999-09-30
EP1640009A1 (fr) 2006-03-29
US7012070B2 (en) 2006-03-14
US7291610B2 (en) 2007-11-06
US7109187B2 (en) 2006-09-19
DE69434584D1 (de) 2006-01-26
DK1640009T3 (da) 2009-01-26
CA2168850A1 (fr) 1995-02-16
US6528676B1 (en) 2003-03-04
ES2315763T3 (es) 2009-04-01
EP0713393A4 (fr) 2000-10-25
HK1089387A1 (en) 2006-12-01
EP0713393A1 (fr) 1996-05-29
US5661143A (en) 1997-08-26
EP1927359A2 (fr) 2008-06-04
CA2168850C (fr) 2007-01-02
ATE411029T1 (de) 2008-10-15
US20060183727A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
DK0713393T3 (da) Östrogenforbindelser som anti-angiogenesemidler
DE69106603D1 (de) Fluorhaltiges Copolymer und dieses enthaltende härtbare Zusammensetzung.
FI943622A7 (fi) Transkoodauslaite
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
EP0598552A3 (fr) Composition polymérique durcissable.
DK0386997T3 (da) Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler
EP0683664A4 (fr) Formulation de taxol.
FI945115A7 (fi) Laite virtaerorakenteen vahvistamiseksi
EP0635553A3 (fr) Composition durcissable.
BR9402890A (pt) Composição de lubrificante baseado em siloxano no segregador de hidrogênio.
EP0607899A3 (fr) Composition photorésistante positive.
FR2713423B1 (fr) Codeur et décodeur différentiels pour la modulation MDP-8 codée en treillis par l'approche pragmatique.
NO954767D0 (no) 4-amino-17 delser som C17-20-lyase- og 5
FR2709891B1 (fr) Convertisseur auto-oscillant du type à ajustement.
DE59105763D1 (de) Tetra-N-glylcidylverbindung und deren härtbaren Gemische.
FR2713444B1 (fr) Composition liquide désinfectante et ses utilisations.
DE69422126D1 (de) Flüssigkristallzusammensetzung, Flüssigkristallvorrichtung und diese verwendende Vorrichtung
IT1281078B1 (it) Composizioni di mescole includenti silice ed un agente antistatico e vulcanizzabili con zolfo, in particolare per la realizzazione di
SE9200762D0 (sv) New topical use
FR2702179B1 (fr) Support adaptable pour liste d'achats.
FR2706003B1 (fr) Roulement pour températures élevées.
EP0652484A3 (fr) Composition pour photoréserve positive.
ES1023430Y (es) Silla para pianistas y similares.
FR2676677B1 (fr) Support d'etau pivotant et orientable.
FR2713414B1 (fr) Dispositif d'amplification à rétroaction.